Our first product candidate, light-activated AU-011, is currently being investigated in a Phase 1b study for the primary treatment of patients with small-to-medium primary ocular melanoma (OM). This open-label, single ascending dose clinical trial is designed to evaluate the safety, immunogenicity and preliminary efficacy of two dose levels of AU-011. AU-011 for ocular melanoma (OM) has been granted orphan drug designation in the United States. If you are a patient or physician and would like to learn more about our clinical trial for light-activated AU-011, please visit www.clinicaltrials.gov or contact firstname.lastname@example.org.
We are also advancing preclinical programs in other conditions where this approach could revolutionize treatment for patients with life-threatening cancers, including bladder and head and neck carcinomas.